| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Barinthus Biotherapeutics plc American Depositary Shares | VTP-300 (HBV003) | Chronic HPV Infection | Phase 2b | Trial Completed | Intramuscular | Antiviral |
| Bausch Health Companies Inc. | Amiselimod S1P6 Modulator | Ulcerative Colitis | Phase 3 | Trial Planned | Oral | Gastroenterology |
| Bausch Health Companies Inc. | Perfluorohexyloctane (NOV03) - (Gobi Study) | Dry Eye Disease Associated With Meibomian Gland Dysfunction | NDA Filing | Ongoing | Ocular | Opthalmic |
| Bausch Health Companies Inc. | NVU-003 (Kalahari) | Dry Eye Disease associated with Meibomian Gland Dysfunction | Phase 3 | Ongoing | Oral | Opthalmic |
| Bausch Health Companies Inc. | IDP-124 | Atopic Dermatitis | Phase 3 | Trial Completed | Topical | Immunology |
| Bausch Health Companies Inc. | Amiselimod S1P6 Modulator | Ulcerative Colitis | Phase 3 | Trial Planned | Oral | Gastroenterology |
| Bausch Health Companies Inc. | Amiselimod S1P6 Modulator | Ulcerative Colitis | Phase 3 | Trial Planned | Oral | Gastroenterology |
| Bausch Health Companies Inc. | IDP-124 | Atopic Dermatitis | Phase 3 | Trial Completed | Topical | Immunology |